Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 01:00 ET | Source: Zelluna ASA

Zelluna ASA – Ex. date

The shares in Zelluna ASA will from today, 4 November 2025, be traded exclusive of the right to participate in the contemplated subsequent offering announced on 3 November 2025. This information is...
November 03, 2025 18:58 ET | Source: Zelluna ASA

Zelluna ASA – Key information relating to subsequent offering

Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the...
November 03, 2025 18:35 ET | Source: Zelluna ASA

Zelluna ASA - Mandatory notification of trade

Reference is made to the private placement (the "Private Placement") and the retail offering through PrimaryBid (the "PrimaryBid Offering") announced by Zelluna ASA on 3 November 2025. Please see the...
November 03, 2025 17:52 ET | Source: Zelluna ASA

Zelluna ASA - Successful private placement and retail offering

Successful private placement and retail offering - Zelluna ASA raises NOK 58 million to advance the world’s first “off-the-shelf” TCR-NK therapy, ZI-MA4-1, into Phase I clinical trials and develop the...
November 03, 2025 10:47 ET | Source: Zelluna ASA

Zelluna ASA – Contemplates private placement

Zelluna ASA – Contemplates private placement of NOK 50-55 million and retail offering to advance into first-in-human trial of its “off-the-shelf” TCR-NK therapy NOT FOR RELEASE, PUBLICATION OR...
November 03, 2025 10:39 ET | Source: Zelluna ASA

Zelluna ASA Reports Third Quarter 2025 Financial Results and Provides General Business Update

Oslo, Norway, 3 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its...
October 09, 2025 01:58 ET | Source: Zelluna ASA

Zelluna Receives Positive MHRA Feedback and Strengthens UK Clinical Strategy for ZI-MA4-1 Paving the Way for First-in-Human Trials in the UK

On track to file CTA by year end 2025, with plan to dose first patients and deliver initial data in 2026Planned UK trial to be led by Prof. Fiona Thistlethwaite at The Christie NHS Foundation Trust, a...
September 10, 2025 02:00 ET | Source: Zelluna ASA

Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday 17 September 2025

Oslo, Norway, 10 September 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces an...
August 20, 2025 01:00 ET | Source: Zelluna ASA

Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update

Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its...
August 14, 2025 06:00 ET | Source: Zelluna ASA

Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation

Oslo, Norway, 14 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites you to a...